Program/Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|
ATA3219: B-cell malignancies | ||||
|
Program/Indication | Phase | |
---|---|---|
ATA3219: B-cell malignancies | Preclinical | |
|
At Atara, we recognize that some patients with serious, life-threatening diseases may not have access to some clinical studies or satisfactory treatment alternatives. That is why we are committed to making every effort to support patients in need of treatment options.
We have designed our clinical studies to evaluate the potential of our investigational treatments in a well-defined cohort of patients with eligibility criteria that allow for appropriate assessment of safety and clinical effect. If you are interested in learning more about our ongoing clinical studies, please contact us at ClinicalStudies@atarabio.com.
This website uses cookies and similar technologies to optimise and improve the experience on our site. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our Privacy Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.